Trial Profile
Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ramipril (Primary) ; Telmisartan (Primary)
- Indications Acute coronary syndromes; Myocardial infarction
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms TERACS
- 15 Jul 2008 New trial record.